HUTCHMED (China) Limited Sponsored ADR (HCM)
(Delayed Data from NSDQ)
$18.13 USD
-0.35 (-1.89%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $18.11 -0.02 (-0.11%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HCM 18.13 -0.35(-1.89%)
Will HCM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HCM
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
HCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Other News for HCM
HUTCHMED Announces Board of Directors Structure
HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript
HUTCHMED (China) Limited 2024 Q2 - Results - Earnings Call Presentation
Hutchmed confident of full year guidance for oncology and immunology
HUTCHMED Reports 2024 Interim Results and Provides Business Updates